Epirubicīna hidrohlorīds - αποτελεσματα

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

phesgo

roche registration gmbh - pertuzumab, trastuzumab - neoplasie al seno - agenti antineoplastici - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

herwenda

sandoz gmbh - trastuzumab - breast neoplasms; stomach neoplasms - agenti antineoplastici - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).